Real-world experience of tixagevimab-cilgavimab pre-exposure prophylaxis in orthotopic heart transplant recipients.

Eloy E Ordaya Eibhlin M Higgins Paschalis Vergidis Raymund R Razonable Elena Beam

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2023)

In this cohort of OHT recipients, no patients developed severe cardiovascular events related to tix-cil. The high incidence of breakthrough COVID-19 could be due to the reduced activity of tix-cil against current circulating SARS-CoV-2 Omicron variants. These results emphasize the need for a multimodal prevention strategy against SARS-CoV-2 in these high-risk patients.

Keyphrases

sars cov
end stage renal disease
cardiovascular events
newly diagnosed
chronic kidney disease
ejection fraction
heart failure
coronary artery disease
peritoneal dialysis
cardiovascular disease
type diabetes
risk factors
gene expression
early onset
atrial fibrillation
dna methylation